Koss-Olinger Consulting’s Surgalign Holdings, Inc. Common Stock SRGA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-35,284
Closed -$6K 313
2023
Q2
$6K Buy
35,284
+9,424
+36% +$9.04K ﹤0.01% 283
2023
Q1
$41K Buy
25,860
+1,968
+8% +$4K 0.01% 259
2022
Q4
$48K Buy
23,892
+13,432
+128% +$33.1K 0.01% 236
2022
Q3
$36K Buy
+10,460
New +$39.9K 0.01% 226
2022
Q2
Sell
-642
Closed -$6K 214
2022
Q1
$6K Buy
642
+258
+67% +$3.92K ﹤0.01% 206
2021
Q4
$8K Sell
384
-1,640
-81% -$43.9K ﹤0.01% 215
2021
Q3
$66K Buy
2,024
+624
+45% +$22.9K 0.01% 228
2021
Q2
$58K Buy
1,400
+380
+37% +$19.5K 0.01% 244
2021
Q1
$67K Buy
+1,020
New +$71.2K 0.01% 233

Other funds holding SRGA

Koss-Olinger Consulting's SRGA Position: Q3 2023 in Review

Koss-Olinger Consulting sold out of Surgalign Holdings, Inc. Common Stock (SRGA) in Q3 2023, closing a stake of 35,284 shares — an estimated $6K sold.

Koss-Olinger Consulting first reported a position in SRGA in Q1 2021 and held it in 9 quarters. The position peaked at $67K in Q1 2021. 4 funds tracked by Wall St. Rank hold SRGA as of Q3 2023.

  • Koss-Olinger Consulting reported no remaining Surgalign Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Koss-Olinger Consulting sold 35,284 Surgalign Holdings, Inc. Common Stock shares in Q3 2023, an estimated $6K.
  • Koss-Olinger Consulting first reported a position in Surgalign Holdings, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Koss-Olinger Consulting's Surgalign Holdings, Inc. Common Stock position peaked at $67K in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Surgalign Holdings, Inc. Common Stock as of Q3 2023.

Based on Koss-Olinger Consulting's 13F filing for Q3 2023, filed 11 Oct 2023.